Boehringer Ingelheim Inks Deal to Expand Patient Access to adalimumab-adbm Injection

Boehringer Ingelheim has entered an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer’s biosimilar to Humira (adalimumab), in the U.S.

Under the terms of the agreement, Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent. Boehringer Ingelheim will continue to commercialize Boehringer Ingelheim-labeled Cyltezo (adalimumab-adbm) injection and Adalimumab-adbm.

“Boehringer Ingelheim is dedicated to broadening access to essential biologic medicines, and our collaboration with Quallent will increase availability of our adalimumab biosimilar for patients living with certain chronic inflammatory diseases,” said Chris Marsh, Senior Vice President of Value and Access at Boehringer Ingelheim. “We’re committed to helping the biosimilar market reach its potential, and this partnership is an important step in enabling greater adoption of these lower-cost options.”

“We are pleased to be working with Boehringer Ingelheim to bring adalimumab-adbm to more patients. Our intent is to offer a copay assistance program, which will provide eligible patients access,” said John Caulfield, President of Quallent Pharmaceuticals Health, LLC. “Quallent was established to help pharmacies give their patients safe and affordable medication, and this collaboration will help us deliver on this goal.”

Quallent will be offering both high-concentration (40 mg/0.4 mL) and low-concentration (40 mg/0.8 mL) citrate-free formulations of adalimumab-adbm as a pre-filled syringe or pen. Adalimumab-adbm’s interchangeability designation for the low-concentration formulation will extend to Quallent’s 40 mg/0.8 mL private-labeled adalimumab-adbm.